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Abstract
Background: We previously reported that the α -1 chain of type 11 collagen (COL11A1), not
normally expressed in the colon, was up-regulated in stromal fibroblasts in most sporadic
colorectal carcinomas. Patients with germline mutations in the APC gene show, besides colonic
polyposis, symptoms of stromal fibroblast involvement, which could be related to COL11A1
expression. Most colorectal carcinomas are suggested to be a result of an activated Wnt- pathway,
most often involving an inactivation of the APC gene or activation of β -catenin.
Methods: We used normal and polyp tissue samples from one FAP patient and a set of 37 sporadic
colorectal carcinomas to find out if the up-regulation of COL11A1 was associated with an active
APC/β -catenin pathway.
Results: In this study we found a statistically significant difference in COL11A1 expression between
normal tissue and adenomas from one FAP patient, and all adenomas gave evidence for an active
APC/β -catenin pathway. An active Wnt pathway has been suggested to involve stromal expression
of WISP-1. We found a strong correlation between WISP-1 and COL11A1 expression in sporadic
carcinomas.
Conclusions: Our results suggest that expression of COL11A1 in colorectal tumors could be
associated with the APC/β -catenin pathway in FAP and sporadic colorectal cancer.
Background
The majority of colorectal carcinomas is sporadic. Muta-
tions in the APC gene are somatically derived and preva-
lent in more than 80% of sporadic cases [1]. A minority
of colorectal cancers is inherited. In familial adenomato-
sis polyposis (FAP), one allele is inactivated in germline,
and the other one somatically [2,3]. In hereditary non-
polyposis colorectal cancer (HNPCC) tumor progression
is evoked by an inherited deficiency in one of the DNA
mismatch repair genes, and a somatic mutation in the
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APC gene is often a result of an increased mutation rate
[4]. The APC protein normally binds to β -catenin in the
cytoplasm and this leads to a rapid degradation of free β -
catenin [5]. Inactivation of the APC gene results in a re-
duced degradation of β -catenin. β -catenin then accumu-
lates in the nucleus, gets attached to Tcf-4/Lef, a
transcription factor activating Wnt target genes [6,7]. β -
catenin has also been suggested to activate the WISP-1
gene, a member of the connective tissue growth factor
family, signaling oncogenic events downstream [8,9].
Collagen is the major component of the interstitial extra-
cellular matrix (ECM). ECM is known to play an active
role in numerous biological processes such as cell mor-
phogenesis, proliferation, migration, differentiation, ap-
optosis as well as carcinogenesis [10,11]. In a previous
study we found that colonic mucosa stromal cells in the
majority of colorectal cancers expressed COL11A1, while
COL11A1 was expressed only rarely in normal colon mu-
cosa [12]. COL11A1 expression was also found in sporad-
ic adenomas although the difference between normal
and adenoma samples was not statistically significant
(12). However, only a limited number of polyps were
available for study [12].
A mutation in the APC gene constitutes an important
event in colorectal carcinogenesis. The Wnt pathway has
been suggested to regulate events also in connective tis-
sue, such as activation of the WISP-1 gene. We therefore
hypothesized that also the up regulation of COL11A1
could be a consequence of an activated Wnt pathway.
The hypothesis fits well with the extra-colonic manifes-
tations in FAP, such as skeleton- eye- and mesenteric
(desmoids) fibromatosis, which could result from an
over-expression of collagens [13]. It is also striking that
an inactivating mutation in the COL11A1 gene involves
the same organs, since affected individuals with Stick-
ler's syndrome show skeleton and ophthalmic manifesta-
tions, such as osteochondrodysplasia, and retinal
detachment and blindness [14].
In this study we investigated the possible up regulation
of COL11A1 in FAP and sporadic colorectal cancer using
tissue samples from one FAP patient and patients with
sporadic colorectal carcinomas.
Materials and methods
Tumors
Twenty-six normal tissue samples from a FAP patient
were collected from ceacum, ascending, transverse, and
descending colon as well as rectum. Fourteen polyps
were collected from the transverse and descending colon
and rectum. The polyps were 2 mm in diameter. The FAP
polyps and 37 sporadic carcinomas and 6 normal tissue
samples were obtained immediately after surgery and
frozen at -70°C. Samples were collected at Umeå Univer-
sity Hospital and Karolinska Hospital with ethical per-
mission according guidelines in each hospital.
RNA and DNA preparation
Total RNA was extracted from frozen tissue by homoge-
nizing with a power homogenizer (IKA Labortechnik) in
Trizol Reagent according to manufacturer's protocol
(Life Technologies) and used for RT-PCR. The RNA was
treated with deoxyribonuclease I (Ambion). DNA was ex-
tracted from frozen tissue by homogenizing with a power
homogenizer (IKA Labortechnik) in STAT 60 due to
manufacturer's protocol (Tel-test "B") and used for PCR.
RT-PCR
Primers designed for COL11A1, COL5A2, WISP-1 and the
internal control GAPDH were used on templates from
tumors and normal tissue for comparison of expression.
Total RNA (2 µg) was reverse transcribed in a total of 40
µl reaction mix, with the following conditions: 5 mM
MgCl2, 50 mM KCL, 10 mM Tris-HCl, pH 8.3, 1 mM
dNTP's, 1 U RNase inhibitor (Perkin Elmer), 2.5 U MuLV
Reverse transcriptase (Perkin Elmer). PCR reaction vol-
ume was 25 µl containing 250 ng of each primer, 250 nM
of dNTP's, and 2.5 U of ampliTaq (Gibco, Life Technolo-
gies). cDNA was diluted 1:2.5 in water and 10 µl was used
for all samples and controls. The primers used were as
follows: COL11A1 5'-AGG AGA GTT GAG AAT TGG GAA
TC-3', 5'-TGG TGA TCA GAA TCA GAA GTT CG-3, for
COL5A2 5'-AAA TGA TGG TGC AGG AGG TC-3', 5'-ATT
GCC AGC TGG ACC TTC-3', for the control GAPDH2f 5'-
GAA GGC TGG GGC TCA TTT G-3', 5'-GAT GGC ATG
GAC TGT GGT CA-3. Thermocycler (PTC 225, Mj Re-
search) was used with an initial denaturation step of
94°C for 5 min, followed by cycles of 94°C for 45 s, 59°C
for 30 s, 72°C for 30 s, and a final elongation step of 72°C
for 5 min. The PCR products were amplified 25, 30, and
36 cycles for linear range and separated on a 1.5% agar-
ose gel containing ethidium bromide, experiments were
repeated three times using the optimal cycle number.
Each experiment was accompanied by amplification of
GAPDH as a control and the intensities of the cDNA
bands for the PCR product were normalized to the GAP-
DH band intensities. The intensity of the bands was esti-
mated with the Image Gauge V3.41 software (Fuji Film
Science).
Sequencing
The germline mutation in exon 15 of the FAP patient was
determined using Big Dye kit sequencing on an ABI se-
quencer (Perkin Elmer).
Protein truncation test (PTT)
A 1.3 kb fragment of the APC exon 15 was amplified using
the apcT7-modified primer 15eT7(5'GGA TCC TAA TACBMC Cancer 2001, 1:17 http://www.biomedcentral.com/1471-2407/1/17
GAC TCA CTA TAG GAA CAG ACC ACC ATG CTT AAA
TAT TCA GAT GAG CAG TTG AA 3') and the antisens
primer apcl5;3 (5'GAG CCT CAT CTG TAC TTC TGC 3')
[15]. Approximately 200 ng genomic DNA and 350 ng of
each PCR primer were dispensed in a 50 µl PCR reaction
buffer (200 µM dNTPs, 1.5 mM MgCl2 and 2 U Taq
polymerase). PCR conditions were 96°C for 1.30 min,
followed by 35 cycles of (96°C for 30s, 60°C for 1.30 min,
and 70°C for 1.30 mm), and a final elongation step at
70°C for 5 min. Protein truncation test (PTT) was per-
formed according to the manufactures instructions
(Promega). Incorporation of 35S-Metionin (Amersham)
was used to detect the translation products after electro-
phoretic separation on a 5% SDS-polyacrylamid gel. The
gel was then dried on a vacuum gel dryer and exposed to
X-ray film (Cronex 4, Sterling Diagnostic Imageing).
LOH
Loss of the APC alleles was tested with PCR on normal
colon mucosa, polyps and tumors. To a 25 µl reaction,
100 ng of DNA, 1.5 mM MgCl2, 200 µM dNTPs, 0.25 µM
of flourochrome marked D5S346F, 0.25 µM D5S346R,
and 1U Taq polymerase (Perkin Elmer), was applied. The
PCR program was 96°C for 2 min, followed by 40 cycles
of 96°C – 30 sec, 50°C – 30 sec, 72°C – 30 sec, and a final
elongation step 72°C for 3 min. The PCR products were
analyzed on a sequencing gel (ABI, Perkin Elmer).
Statistical analysis
The difference between mRNA expression in normal
samples and carcinomas in sporadic cases, and in nor-
mal tissue and polyps from the FAP patient was tested by
a non-parametric method, Mann-Whitney U test, where
p < 0.05 was considered systematic/statistically signifi-
cant. Correlation between COL11A1 and WISP-1 expres-
sion was studied by linear correlation and calculated by
Sperman rank order correlation coefficient. Experiments
and analyses were made twice.
Results
Correlation between APC/β -catenin pathway and 
COL11A1 expression in FAP
First the APC germline mutation was determined using
sequencing. It was a deletion of 4 base pairs at nt 4043 in
exon 15, codon 1347, confirming the diagnosis of FAP in
the patient. Twenty-six samples from normal colon tis-
sue and 14 polyps from the FAP patient were tested for
COL11A1 expression and inactivating mutations of the
APC gene. RNA extracted from fresh frozen samples
from the resected colon in the FAP patient were then
studied using a semi-quantitative RT-PCR. Grossly nor-
mal biopsies from caecum, ascending, transverse, de-
scending colon, and rectum, as well as polyps from
ascending and descending colon, and rectum, were ana-
lyzed. Using a three fold reproduced RT-PCR experiment
(examples shown in figure 1), it was shown that polyps
expressed COL11A1 to a statistically significantly higher
level than normal tissue samples (p = 0.001) (figure 2a).
The relative lack of RNA made it possible only to make
one northern blot experiment using a small number of
samples. It was not possible to confirm the results in this
experiment, since no signal for COL11A1 was obtained
for normal tissues or polyps. The FAP adenomas showed
a similar level of expression as the sporadic adenomas in
our previous study [12]. A comparison of the levels of
COL11A1 expression between FAP adenomas and spo-
radic colonic carcinomas was demonstrated in a RT-PCR
experiment where FAP adenomas and sporadic colorec-
tal tumors were run at the same time (figure 2b). The
cancers expressed the RNA to a much higher degree than
adenomas. In our previous study, COL11A1 and COL5A2
were co-expressed in sporadic colorectal cancer [12]. We
therefore tested whether COL5A2 expression was also
associated with COL11A1 in FAP adenomas. However, no
expression of COL5A2 was found in FAP normal cells or
FAP adenomas (examples shown in figure 1). Normal
FAP tissue where cells have one APC-allele mutated in
germline did not express COL11A1, why we hypothesized
that a complete inactivation of the wild-type allele by a
second mutation was necessary for the up-regulation of
COL11A1. The 14 FAP adenomas were therefore studied
for inactivating second mutations of the wild-type allele
by mutation screening using protein truncation test
(PTT) and loss of heterozygosity (LOH) studies. All pol-
yps tested had mutations and/or LOH of the wild type al-
lele (figure 3a). Thus, all FAP samples gave evidence for
an inactivated wild-type allele. This supports the idea
that all polyps were established through an inactivation
of the APC gene on both alleles, which triggered the ade-
Figure 1
Example on RT-PCR comparing expression of GAPDH (C),
COL11A1 (α 1(11)), COL5A2 (α 2(5)) in normal (N), and polyp
tissues (P) from one FAP patient. AN, TN, DN, macroscopi-
cally normal tissue taken from ascending, transverse,
descending colon respectively, TP, Polyp from transverse
colon, DP, Polyp from descending colon, RP, Polyp from rec-
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noma formation and maybe also the up-regulation of
COL11A1 in FAP.
Correlation between APC/β -catenin pathway and 
COL11A1 expression in sporadic colorectal cancer
In an attempt to relate the up-regulation of COL11A1 ex-
pression to the inactivation on the APC gene in sporadic
cancer, a panel of 37 sporadic colorectal carcinomas was
used.
These samples were already studied for COL11A1 expres-
sion by using RT-PCR in a previous study [12]. Mutations
of the APC gene were searched for by using the protein
truncation test (PTT) of exon 15, known to contain the
majority of mutations in the so-called mutation cluster
region (MCR) (figure 3b). In total 22 of 37 (59%) tumors
had a truncated mutation in exon 15. There was no cor-
relation between COL11A1 expression and a truncating
mutation in exon 15 of the APC gene. However, the path-
way can be activated by other mutations outside exon 15,
by mutations not detected by our method, by mutations
in other Wnt related genes or even epigenetic alterations.
Therefore, we hypothesized that COL11A1 might be up-
regulated in a similar fashion as and together with WISP-
1. Using the expression of WISP-1 as an estimate of APC/
β -catenin activation, a study was undertaken to find out
if COL11A1 expression correlated with the expression of
WISP-1 in the sporadic colorectal tumor samples. There
was a statistically significant up-regulation of WISP-1 in
sporadic carcinomas compared to the expression in nor-
mal tissue (p < 0.002). The expression of COL11A1 cor-
related well with the up-regulation of WISP-1
(correlation coefficient = 0.72, p < 0.001) in the tumors
(Fig. 4). The expression of WISP-1 in FAP samples did
not differ between normal tissue and polyps (p < 0.72)
with the method used by us.
Discussion
In this study we found a statistically significant over-ex-
pression of COL11A1 in polyps from a patient with FAP.
We have previously shown that COL11A1 was upregulat-
ed in the majority of sporadic colorectal cancer [12]. We
Figure 2
Box Plots illustrating the difference between expression of
COL11A1 showing FAP normal tissue samples compared to
FAP polyps (2a), and FAP polyps compared to sporadic
colorectal carcinomas (2b). The boxes mark the interval
between the 25th and 75th percentiles. The whiskers denote
the interval between the 10th and 90th percentiles. An obser-
vation that lies more than 1.5 times the height of a box from
the box is defined as outliner and when an observation lies
more than 3 times the height of a box from the box, it is
defined as an extreme value.
Figure 3
Protein truncation test (PTT) on a) FAP adenoma samples,
wt, wild type allele, mut, germline mutated allele, other bands
indicate secondary mutations of either the wild type or the
germline mutated allele. TP, polyp from transverse colon,
DP, polyp from descending colon, RP, polyp from rectum,
AN, normal FAP tissue taken from ascending colon. The
marker CFA756 was used to approximate the size in KD
(left), b) examples of sporadic colorectal carcinomas.BMC Cancer 2001, 1:17 http://www.biomedcentral.com/1471-2407/1/17
hypothesized that the Wnt pathway could be directly in-
volved in the up-regulation of COL11A1 in similarity to
the extracellular molecule WISP-1. The Wnt pathway is
involved in development of dorsal mesoderm induction
and is also likely to be involved in development of the gut
in humans. This is consistent with the expression of
COL11A1 in human fetal colon as well as other human de-
veloping tissues, mainly skeleton and tendon [16,17].
COL11A1 is up-regulated in the APC/β -catenin pathway in 
FAP and sporadic colorectal cancer
COL11A1 was up-regulated in small colorectal polyps,
from one FAP patient, but to a lower degree than seen in
sporadic carcinomas. This supports the hypothesis that
the APC/β -catenin pathway could influence COL11A1 ex-
pression in FAP. Not all sporadic colorectal carcinomas
expressed COL11A1 in our previous study [12]. There was
no association between an exon 15 truncating APC muta-
tion and the expression of COL11A1 in the 37 sporadic
colorectal tumors in this study. In FAP there are frequent
examples of an inactivation of both APC-alleles in tu-
mors, while in attenuated APC and sporadic colorectal
cancer this is not equally frequent [18,19]. Still, the APC/
β -catenin pathway is supposed to be involved in the vast
majority of sporadic tumors, why we next used the ex-
pression of WISP-1 as an estimate of APC/β -catenin
pathway activation in the sporadic tumors. WISP-1 is a
member of the connective tissue growth factor family,
shown to be over-expressed in 80% of colonic adenocar-
cinomas. It has been suggested to be activated by β -cat-
enin [8], active in the Wnt pathway [20,21]. WISP-1 was
up-regulated in sporadic tumors and there was a good
correlation between COL11A1 and WISP-1 expression in
the tumors. This correlation suggests that the over-ex-
pression of COL11A1 could be related to the APC/β -cat-
enin pathway. However, some sporadic tumors with a
truncating mutation in exon 15 did not show an up-regu-
lation of the COL11A1, and there must be some explana-
tion for that. One possible explanation could be the RT-
PCR technique used, or that RNA for some samples
could have been degraded for these particular genes even
though RNA was not degraded for control genes. It is
also possible that there is no association with the APC/β -
catenin pathway
FAP adenomas showed no up-regulation of WISP-1 or 
COL5A2
WISP-1 was also expressed in normal tissue as well as in
FAP, but no clear up-regulation of WISP-1 could be de-
termined in FAP adenomas. However, if there is an asso-
ciation with COL11A1 expression, the much lower
expression in adenomas may explain the lack of detecta-
ble up-regulation of WISP-1. The fact that COL5A2 was
not expressed in the FAP adenomas, in contrast to spo-
radic carcinomas, suggests that COL5A2 could be in-
volved in the transition from a benign to malignant state
in colorectal cancer. Alternatively, the COL5A2 (as well
as WISP-1) could be associated with a much higher ex-
pression of COL11A1, as seen in sporadic colorectal can-
cer.
Is the mechanism of COL11A1 transcription in FAP differ-
ent from that in sporadic colorectal cancer?
In FAP there may be a direct regulation of COL11A1 in
the stromal cells since also the stromal cells have muta-
tions in the APC gene. In sporadic colorectal cancer, the
pathway must be activated and influence stromal cells by
a somatic mutation in an epithelial cell. In the case of
WISP-1, a model has been proposed where epithelial
cells express WISP-1 to activate the Wnt pathway in stro-
mal cells, which answer with secreting WISP-1, which in
turn stimulates growth. A paracrine and then an auto-
crine production of WISP-1 might efficiently stimulate
epithelial cells to continue unregulated proliferation and
eventual tumor formation [9]. There may be a similar
way for how the APC mutation in epithelial cells can in-
duce a reaction in surrounding stromal fibroblasts in
sporadic colorectal cancer.
Conclusion
The results from this study suggest that the up-regula-
tion of COL11A1 in early adenomas in FAP and in sporad-
ic colorectal carcinomas is associated with an activated
APC/β -catenin pathway. The expression of COL11A1
could directly contribute to tumorigenesis in fibroblasts
in FAP and explain osteomas and desmoids, or indirectly
to polyp-formation and tumor progression in sporadic
colorectal cancer.
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Figure 4
Diagram showing the correlation between COL11A1 and
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